Merck & Co. , Inc. today
Merck & Co. , Inc.
- 52 weeks
- 86.27 dollars
▼
134.63 dollars
- Profit
- 3.74 %
- P/E ratio.
- 12.86
- The target price
- 117.94 dollars
Big Pharma has been subjected to a lot of organizers and consumers as an acidity in the industry. As such, the market can be ruthless when companies misses expectations or expectations a little. This is the case with Merck & Co. Inc. New York: MRKAs the shares lost more than 10 % after reporting the results of the fourth profits of 2024.
While the company informed its victory over the profitability of the stock by 11 cents, as revenues increased by 6.8 % on an annual basis to 15.62 billion dollars, overcoming the unanimity estimates of $ 15.48 billion, the guidance was 2025 that shook the investor’s confidence. MERCK has made the arrow profit from $ 8.88 to $ 9.03 for estimates of an analyst of $ 9.13 from 64.1 billion dollars to $ 65.6 billion, which is no less than unanimity estimates of $ 67.07 billion.
The decrease can be considered an opportunity to buy for the giant of the medical sector. Here are 4 non -mental reasons for buying this decline in Merck shares.
1) It was a lack of guidance due to a thoughtful stoppage in China
Both upper and lower rush deficiency can be attributed to the deliberate Merck decision to stop Gardasil’s shipments to China from February to mid -2015.
Merck & Co. , Inc. Marketrank ™
- In general, Marketrank ™
- 100 percentage percentage
- Analyst classification
- Moderate purchase
- The upward trend/negative side
- 35.6 % up
- The level of short attention
- correct
- Profit power
- strong
- Environmental result
- -2.86
- Feelings of news
- 0.85
- Trading from the inside
- Get shares
- Bruges. Profit growth
- 10.10 %
See full analysis
Gardasil is the HPV vaccine (HPV), which is used to prevent diseases and cancers caused by HPV. Gardasil’s sales in the fourth quarter decreased by 17 % year on an annual basis to $ 1.55 billion, which was lost by analysts of $ 1.61 billion. For the full year 2024, Gardasil achieved $ 8.6 billion in sales, a 3 % decrease.
The reason for stopping the temporary shipping is to give the market an opportunity to work through its store in China and allow distributors to control the inventory of the request. This clearly indicates the problem of demand, but Merck insists that growth will resume in the second half of 2025. GSK PLC Nyse: gsk Cervarix HPV vaccine.
2) Merck pipeline from drugs is worth more than $ 50 billion
At its collective conference, Rob Davis, CEO of MERCK, stated that they have 20 potential growth engines to treat possible new pipelines, almost all of them have great growth opportunities. Some of them include their overrevair and Capvaxive pulmonary vaccines, which have now been launched in the United States. MERCK has many promising treatments in the development of stage 3. In fact, MERCK doubles three times the number of medicines in the development of the third stage in the third stage in the past three years. Davis said, “Based on the great progress, we see more than $ 50 billion in the opportunity of possible revenue from these programs,” Davis said.
3) Merck stock offers a value at these levels
After 10 % decrease, MERCK shares are now traded with only 11.45X front profits compared to the average industry of 30.22X. The 12 -month prices (TTM) (T/E) at 18.29 are less than 10 years of P/E from 25.36. The ratio of the price to the sale (P/S) is 3.45 compared to the average industry of 4.31. His shares pay an annual profit revenue of 3.71 % with a debt rate to strong ownership rights of 0.79 and A+ credit classification for its public budget, generating a cash flow of TTM with a value of $ 18.26 billion. The shares are traded by 35.3 % of their highest levels, 37.91 % of the target consensus analyst, and at its lowest levels for three years.
4) The shares of MRK are close to the triple monthly support level
Triple support consists of three overlapping levels of overlapping lines, fenders or indicators. The broader time frame charts tend to have more stable price levels.
The MRK monthly chart shows a sharp decrease from its highest level. The stock is close to supporting the triple price level. The three support levels are approximately $ 86.02 to $ 85.48, followed by another double support at $ 83.05 to 82.56 dollars. The level of the first triple support consists of the extension of the Tails (purple) line, price support at $ 86.02 (green), and the monthly VWAP support at $ 85.48 (Orange). The second level of double support is with $ 86.02 (green) and $ 82.56 support FIB 0.076 (light green). everyone The support group range ranges between $ 82.56 to $ 86.02.
Executive options strategiesSaudis investors can think about using withdrawals from FIB to buy DIP. If the shares are set, the writing of the covered call on the ups of the ups of the fibs implement the wheel strategy for income as well as the annual futures dividends revenue by 3.71 %.
Before you think about Merck & Co. , Inc. , You will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts whispered quietly to their customers to buy now before he wiped the broader market … and it was not Merck & Co. , Inc. In the list.
While Merck & Co. , Inc. She currently has a “moderate purchase” classification among analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
With the spread of data and electric cars, the electrical network will get more tension. Download this report to find out how energy shares can play a role in your wallet with the continued growth of global energy demand.
